Skip to content

Clinical trials

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Clear all

21 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20141
20191
20204
20211
20222
20231
20245
20253
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting12
Active, not recruiting3
Not yet recruiting3
Unknown status2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Tongji Hospital3
Fondazione Policlinico Universitario Agostino Gemelli IRCCS2
Assistance Publique - Hôpitaux de Paris1
Assistance Publique Hopitaux De Marseille1
Beijing Tiantan Hospital1
CRISPR Therapeutics1
Cedars-Sinai Medical Center1
Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul1
Fondazione Italiana Sclerosi Multipla1
Hoffmann-La Roche1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease21
Neuromyelitis Optica15
Multiple Sclerosis14
Autoimmune Diseases of the Nervous System7
Encephalomyelitis, Acute Disseminated4
Myasthenia Gravis4
Demyelinating Diseases3
Optic Neuritis3
Autoimmune Diseases2
Guillain-Barre Syndrome2

Trials

Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.